GLA and Fabry disease: In a clinical study on eight patients with Fabry disease who took enzyme replacement therapy (agalsidase-alfa, 0.2 mg/kg every week) for two years and were serially followed during this period: there were mixed results; white matter lesions stayed stable in three patients, worsened in one patient, and diminished only in one patient [47].